FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 126 filers reported holding FATE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,756,000 | +36.4% | 99,950 | -0.4% | 0.00% | 0.0% |
| Q4 2018 | $1,287,000 | -57.6% | 100,339 | -46.1% | 0.00% | 0.0% |
| Q3 2018 | $3,034,000 | +175.3% | 186,284 | +91.6% | 0.00% | 0.0% |
| Q2 2018 | $1,102,000 | +9.4% | 97,205 | -5.8% | 0.00% | 0.0% |
| Q1 2018 | $1,007,000 | +71.3% | 103,173 | +7.2% | 0.00% | – |
| Q4 2017 | $588,000 | +45.5% | 96,262 | -5.6% | 0.00% | – |
| Q3 2017 | $404,000 | +8.3% | 102,021 | -11.5% | 0.00% | – |
| Q2 2017 | $373,000 | – | 115,275 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |